Lucid Diagnostics is a high-growth, commercial-stage medical diagnostics company focused on the early detection of esophageal precancer and cancer through its innovative EsoGuard Esophageal DNA Test and EsoCheck Cell Collection Device. The company's investment thesis centers on its ability to disrupt the traditional, highly invasive endoscopy screening paradigm for patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal adenocarcinoma. While currently unprofitable due to heavy commercialization and clinical utility study investments, Lucid is building significant commercial momentum, as evidenced by growing test volumes and key contract wins, such as its national contract with the U.S. Department of Veterans Affairs (VA). The primary near-term catalyst is securing broad Medicare coverage through the MolDX program, which would unlock substantial high-margin revenue and accelerate path-to-profitability.